Antinuclear Antibodies in Localized Scleroderma

✍ Scribed by Kazuhiko Takehara; Yasuoki Moroi; Yasuharu Nakabayashi; Yasumasa Ishibashi

• Publisher: John Wiley and Sons
• Year: 1983
• Tongue: English
• Weight: 406 KB
• Volume: 26
• Category: Article
• ISSN: 0004-3591
• DOI: 10.1002/art.1780260506

✦ Synopsis

When HeLa cells were used as the substrate for detection by the indirect immunofluorescence method, antinuclear antibodies were demonstrated in 16 of 22 (72.7%) sera from patients with localized scleroderma. When mouse kidney sections were used, the positive rate for antinuclear antibodies was 50% (11 of 22). In the 3 subgroups of localized scleroderma, frequencies of antinuclear antibodies on HeLa cells were as follows: morphea, 50% (2 of 4), generalized morphea, 100% (6 of a), linear scleroderma, 67% (8 of 12). Antibodies to centromere, Scl-70, nuclear RNP, Sm, and SS-B antigens were not detected in any patient with localized scleroderma. The high frequency of antinuclear antibodies in localized scleraderma sera suggests that localized scleroderma is a disease which, though different from diffuse scleroderma, also involves an immunologic abnormality.

Scleroderma is a chronic disease of unknown etiology and is divided into two types: localized scleroderma and diffuse scleroderma, or progressive systemic sclerosis (PSS). Tuffanelli and Winkelmann classified the two as follows: localized scleroderma includes